Proposed changes to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules would 1) remove the NIH protocol submission, review, and reporting requirements under Appendix M of the NIH Guidelines and 2) modify the roles and responsibilities of the Recombinant DNA Advisory Committee (RAC).
You will not select “Add New Study” and complete Section 3 - Protection and Monitoring Plans in a grant application for a delayed onset study.
The Behavioral and Social Sciences Clinical Trials Template will inform an update to the Clinical e-Protocol Writing Tool, which applicants can use as a guide when preparing comprehensive clinical protocols for Phase 2 and 3 clinical trials.
To apply for the Expanding Extramural Research Opportunities at the NIH Clinical Center funding opportunity announcement, you'll first need to obtain a letter from the Clinical Center director to confirm that the Clinical Center facilities will be able to accommodate your proposed research.
NIAID will now support Academic Research Enhancement Awards focused on undergraduate institutions or academic components in which the undergraduate student enrollment is greater than the graduate student enrollment.
NIAID will help current grantees recruit and support students, postdocs, and other eligible investigators from diverse backgrounds to work on research experiences integral to the grant's ongoing research, with the potential to contribute significantly to the career development of the candidates.
Check out a list of five new resources, which includes helpful information on informed consent, intellectual property security, and early-stage investigator status, to ensure you're following the latest guidance on these topics.
Within 120 days of your project period’s end date, you must submit a Final Research Performance Progress Report, Final Federal Financial Report, and Final Invention Statement and Certification.
NIH issued four funding opportunity announcements that focus on solutions to widely recognized issues in developing safe and effective regenerative medicine therapies, contribute an enhanced understanding of stem cell product attributes, and promote data sharing.
Apply now to examine the correlations between HIV drug resistance genotypes and in vitro phenotypes of the virus, virologic outcomes, and treatment success.
Apply to explore novel central nervous system (CNS)-targeted drug delivery platforms and focus on product development activities to identify and eliminate CNS viral reservoirs that potentially lead toward a cure or lifelong remission of HIV infection.
Beginning with grant applications for fiscal year 2019 funding, NIAID will limit the total number of predoctoral and postdoctoral training slots to a maximum of 10 trainee slots per training grant in any given year.
Find concise notes on updates to the Human Subjects System and the Application Submission System & Interface for Submission Tracking.
You may be tempted to include as much information as possible in your grant application, but this often results in an overly dense document with data and text not directly relevant to the key components of a successful application.
NIH is implementing short-term policy flexibilities for some requirements affecting prospective basic science studies involving human participants.
Small businesses: Don't miss your chance to submit a proposal to complete research in one of many topic areas of interest to NIAID.
Conduct research using NIH Clinical Center resources like nursing, beds, imaging, safety oversight, and more.
NIAID recently released two funding opportunity announcements to support research activities that will provide foundational information to advance the development of a universal influenza vaccine.
Consider applying for a short-term grant to better understand the immunologic events that occur during blood feeding by hematophagous arthropods such as ticks and mosquitoes.
Grantees may choose to implement three of the Common Rule’s provisions immediately, even though HHS is delaying implementation of the Common Rule until January 21, 2019.
NIAID’s ImmPort team is committed to ensuring that the public data sharing repository of immunology research and clinical trials meets community standards and best practices for open data and open science.
NIH recently issued a notice to remind researchers that the resubmission policy allows investigators to follow their unfunded resubmission (A1) with a new application (A0) and does not require the second A0 to be significantly different from the A1.
The AIDS and Related Research integrated review group's study sections are now publicly accessible online, and their rosters and meetings information will be online soon.
The Chemical Countermeasures Research Program focuses exclusively on enhancing the nation's medical response capabilities to protect the civilian population during public health emergencies involving the release of chemical threat agents.
Through this funding opportunity, we will support research to characterize tuberculosis transmission events within the Transmitter-Recipient Cluster Chains in high-burden settings, including elucidating the impact of HIV co-infection on transmission rates.
We remind you of an opportunity to develop new or improved informatics tools and methods to improve and facilitate reusing shared data in NIAID's data repository ImmPort.
NIAID looks to fund a leadership group to conduct clinical research studies and clinical trials that will impact understanding, preventing, diagnosing, and treating antibacterial resistance infections.
Small businesses: don't miss an opportunity to receive individualized assistance to transition developed products into the marketplace.
NIAID adjusted fiscal year paylines for training, fellowship, and small business grants.
Review two changes in eRA Commons that will make completing your next Research Performance Progress Report even easier.
NIH’s Rigor and Reproducibility page is still the best place to start when completing the Research Plan of your next application. Pay close attention to the listed “Examples of Rigor in Applications” within the Resources section.
NIH posted an SBIR/STTR Clinical Trials Funding Opportunity Decision Tree, which, based on your answers, will direct you to the funding opportunity announcement that best matches your intended research.
If you are eligible for continuous submission, you may submit your R01, R21, or R34 application at any time, but NIH will assign it to an Advisory Council round based on a set schedule.
Consider applying to NIH's Loan Repayment Program if you’re an eligible doctoral-level clinician or researcher who’s committed to conducting NIH-qualified research. Should you be awarded, we will repay up to $35,000 each year toward your qualified educational debt.
An organization that received no more than $8 million in total NIAID grant and cooperative agreement support (direct awards) in the last five years is eligible to apply. Previously, the limit was $2.2 million in total NIH funds.
If you have an award to carry out a clinical trial, ensure your research is in good standing by identifying the responsible party, knowing your ClinicalTrials.gov requirements, and creating a system to ensure compliance.
Bilateral programs are one of many mechanisms NIAID uses to establish research cooperation between Institute-supported U.S. scientists and foreign collaborators.
NIAID has amended the solicitation to include a research area focused on developing a universal influenza vaccine: Collaborative Influenza Vaccine Innovation Centers (CIVICs).
NIAID seeks research to determine the roles and interactions of immune cells at the maternal-fetal interface that mediate a healthy pregnancy as well as during encounters with infectious agents, vaccinations, or ionizing radiation.
Consider applying if you're capable of developing modeling and simulation tools to examine HIV transmission dynamics and estimate the impact of treatment and prevention interventions and strategies.